Progressive and Sustained Disease Control in Patients with Atopic Dermatitis (AD) Aged 12–17 Years Treated with Tralokinumab for 52 Weeks. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 2, p. s377, 2024. DOI: 10.25251/skin.8.supp.377. Disponível em: https://skin.dermsquared.com/skin/article/view/2680. Acesso em: 18 apr. 2025.